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Edited by Sandro SonninoAbstract MRP2(/ABCC2) excretes amphiphilic organic anions
into bile, and associates with detergent-resistant bile canalicular
membrane domains (DRM). Here, we have evaluated sensitivi-
ties of MRP2 transport function and DRM association by titrat-
ing the cellular cholesterol content. We demonstrate that the role
of cholesterol in the partitioning of MRP2 to DRM can be sep-
arated from the role of cholesterol in the function of MRP2, such
that (i) cholesterol is not necessary for the polarized distribution
of MRP2 at the canalicular membrane, (ii) partitioning into
DRM is not required for MRP2 function, yet (iii) the presence
of cholesterol is necessary for transport activity.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The ABCC family multidrug resistance-associated protein
(MRP)2 (or ABCC2) [1,2], is exclusively expressed at the
hepatocyte bile canalicular (BC) membrane, where it is
involved in biliary excretion of organic anions including
glutathione conjugates, glucuronide conjugates, sulfated con-
jugates of bile salt, and nonconjugated compounds [3–5].
The bile canalicular membrane of hepatocytes is enriched in
cholesterol and sphingomyelin [6,7]. This unique composition
allows canalicular membranes to resist the detergent-like eﬀect
of bile acids [8]. The canalicular membrane contains choles-
terol- and sphingolipid-rich TX-100-resistant and low-buoyant
density membrane (DRM) fractions. These accommodate
membrane proteins including aquaporins, ion channels, anion
exchangers, and some, but not all [e.g. MDR1 [9]], ABC trans-
porters, among which MRP2 [10,11]. The association of apical
plasma membrane proteins with DRM, which may represent
cholesterol-dependent lipid microdomains or rafts, has been
correlated to their prior sorting and traﬃcking, and to their
functioning. Indeed, the transporter function of ABC trans-
porters is conceivably regulated by membrane lipids as they
are inevitably incorporated in the lipid bilayer and interact
with membrane components [12]. The physiological signiﬁ-*Corresponding author.
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unclear.
In this study, we have used HepG2 cells which develop BC
membranes and endogenously express MRP2 at the canalicu-
lar membrane. The activity of this protein can be quantita-
tively assessed by visualizing ﬂuorescent MRP2 substrate
accumulation in BC lumens. We have examined the eﬀect of
cholesterol depletion on the transport function of MRP2,
and whether DRM association is necessary for MRP2
transport function.2. Materials and methods
2.1. Cell culture
HepG2 cells (ATCC, Manassas, VA) were cultured as described
elsewhere [9]. In brief, HepG2 cells were grown at 37 C in DMEM
supplemented with 10% heat-inactivated (56 C, 30 min) fetal bovine
serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 lg/ml strepto-
mycin, under a 5% CO2, air atmosphere. For microscopy and biochem-
istry experiments, HepG2 cells were grown onto glass coverslips and
plastic dishes, respectively.
2.2. DRM preparation and immunoblot
Cells were cultured in 100 mm dish for 24 h and TX100-DRM
preparation was performed as described previously [9]. In brief, cells
grown to conﬂuence were rinsed with PBS and lysed for 20 min in
TNE (20 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1%
Triton X [TX] 100, and protease inhibitors) buﬀer on ice. Lysates were
scraped from the dishes and homogenized by passing through a 25-
gauge needle. The extracts were brought to 40% sucrose and placed
at the bottom of 5–35% sucrose gradient. Gradients were centrifuged
for 20 h at 40000 rpm at 4 C in a Beckman SW 41 rotor. Fractions
of 1 ml were harvested from the top of the gradient. Proteins were
recovered by trichloroacetic acid (TCA) precipitation. TCA pellets
were solubilized in 100 ll of Laemmli buﬀer and 20 ll of each sample
were used for SDS–PAGE. After transfer to a PVDF membrane, pro-
teins were detected with speciﬁc antibodies, and revealed by enhanced
chemiluminescence kit (GE Healthcare Bio-Sciences, Little Chalfont,
UK). MRP2 was detected with the M2III6 antibody (1:200) (Alexis
Biochemicals, San Diego, CA).
2.3. Cholesterol measurement
Cholesterol concentration in control, cholesterol-depleted, and
cholesterol-repleted cells was determined spectrophotometrically by a
cholesterol oxidase/peroxidase assay [13].
2.4. 5-Chloromethylﬂuorescein (CMF) eﬄux experiment
Cells were treated with buﬀer (control), 50 lM of MK571, an MRP2
inhibitor (kindly provided by E. Vellenga, UMC Groningen, The
Netherlands), or 13.3 mM metyl-b-cyclodextrin (MbCD) at 37 C.
Then cells were mounted on a CMF diacetate (CMFDA; 5 ng/ml, ﬁnal
1% ethanol)/HBSS droplet. After incubation at 37 C for 5 min,
samples were immediately analyzed with epiﬂuorescence microscopyblished by Elsevier B.V. All rights reserved.
Fig. 1. Eﬀect of cholesterol depletion and repletion on the localization
and DRM association of MRP2. (A) HepG2 cells were treated without
(HBSS 20 0) or with 10 mM MbCD (CD 20 0) for 20 min at 37 C, then
cells were ﬁxed and stained for MRP2 and Rdx. Cell shapes were
outlined for clarity. Note that MRP2 located on BC was resistant to
MbCD treatment. (B) Immunoblot of MRP2 in DRM fractions. Cells
were treated with HBSS (HBSS 20 0) or with 10 mMMbCD for 10 min
(CD 10 0) and 20 min (CD 20 0) at 37 C. Also, cells treated with 10 mM
MbCD for 20 min were subsequently incubated with MbCD/choles-
terol for 30 min to replenish cholesterol (CD200 ﬁ CD/Chol). Frac-
tions 1 and 10 correspond to the lightest (top) and heaviest (bottom)
fractions, respectively. Fractions 3–5 corresponds to typical DRMs.
(C) Cellular cholesterol content was measured and shown as control
cells before MbCD treatment (0 0). (D) Filipin was used to stain for
cellular cholesterol in control, MbCD-, and MbCD/cholesterol-treated
cells.
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ﬂuorescent pixel intensity in at least 50 BC of comparable size per con-
dition was measured and expressed as percentage of control ± S.D.
2.5. Immunoﬂuorescence
Indirect immunoﬂuorescence was performed as described previously
[9]. Cells were washed with Hanks balanced salt solution (HBSS),
ﬁxed with 4% paraformaldehyde for 30 min at RT, and permeabilized
with 0.1% TX100 in HBSS for 10 min at 37 C. After blocking in 1%
PBS/bovine serum albumin (BSA), cells were incubated for 1 h at room
temperature with primary antibodies. After three washes in HBSS,
cells were incubated for 1 h at room temperature with ﬂuorescently
labeled secondary antibodies. Primary antibodies were M2III6
(1:500), Radixin (1:1000) (Sigma), ZO-1 (1:100). Secondary antibodies
were Alexa Fluor-488 labeled goat-anti-mouse antibody (1:500) (Invit-
rogen), TRITC-labeled goat-anti-rabbit antibody (1:500) (Invitrogen).
DNA was stained with Hoechst 33342 (1:1000) (Invitrogen). Filipin
(Polyscience Inc.) was used at a concentration of 50 lg/ml at room
temperature for 30 min.
To determine the percentage of MRP2/radixin-positive BC, BC were
ﬁrst identiﬁed and counted by phase contrast illumination, and then
classiﬁed as being MRP2/radixin-positive or -negative under epiﬂuo-
rescence illumination
2.6. Cholesterol depletion and replenishment
Cells were incubated with 10 mM MbCD at 37 C to deplete choles-
terol. Cholesterol replenishment was carried out by incubating the cells
with preformed MbCD/cholesterol-complexes as described previously
[14]. Brieﬂy, after cholesterol depletion, HepG2 cells were washed with
serum-free medium and incubated 3 h at 37 C in the presence of
CD-cholesterol (CD/Chol) complexes (400 lg/ml cholesterol) diluted
in serum-free medium.
2.7. Lactose dehydrogenase (LDH) leakage assay
LDH leakage was determined using a Cytotoxicity Detection Kit
(Roche Applied Science, Mannheim, Germany), according to the
manufacturers instructions. Cells treated with 1% TX100 were set as
100% LDH leakage sample.
2.8. ATP measurement
Cellular ATP concentration and leakage into the medium was deter-
mined using an ATP Determination Kit (Invitrogen), according to the
manufacturers instructions. As a positive control for cellular leakage,
cells were treated with 1% TX100 at 37 C for 5 min to release cellular
ATP, or treated with metabolic inhibitors (5 mM NaN3 and 50 mM
2-deoxy-O-glucose) to deplete cellular ATP.
2.9. Analysis of tight junction integrity
Tight junction integrity was checked by using N-(N-[6-[(7-nitrobenz-
2-oxa-1,3-diazol-4-yl)amino]caproyl])-sphingosylphosphorylcholine
(C6-NBD-SM) as a ﬂuorescent probe [15]. Brieﬂy, cells were cooled to
4 C by washing with ice-cold HBSS, and incubated with 4 lM C6-
NBD-SM for 30 min at 4 C to label the basolateral plasma membrane
while preventing endocytosis. The cells were then observed under
ﬂuorescence microscopy to detect whether the ﬂuorescent lipids had
diﬀused from the basolateral surface domain to the BC surface
membrane.3. Results and discussion
MRP2 exclusively localizes to the apical BC membrane of
HepG2 cells showing nearly complete colocalization with
Rdx (Fig. 1A). Both the staining intensity and distribution pat-
tern of these two proteins were not aﬀected after treatment
with MbCD for up to 20 min (Fig. 1A), when cellular choles-
terol content is reduced to 24% of control (Fig. 1C). Already
after a 10 min treatment of the cells with MbCD, cholesterol
was no longer visible with ﬁlipin staining in both basolateral
and BC membrane domains (Fig 1D), which suggests a rapidequilibration of sinusoidal and BC plasma membrane-associ-
ated cholesterol. The polarized distribution of MRP2 at the
BC membranes was semi-quantiﬁed by determining the per-
centage of MRP2-positive BC per 100 cells. Thus, in control
and cholesterol-treated cells a comparable number of BC
structures per 100 cells were counted (15.2 ± 2.5 in control
samples versus 14.7 ± 2.2 in MbCD-treated samples;
means ± S.D. of triplicate determinations), and these were all
positive for MRP2. Similar results were observed for Rdx
and other resident bile canalicular proteins (data not shown).
Therefore, cholesterol is not necessary for the polarized distri-
bution of MRP2 in BC membranes.
We next monitored MRP2 partitioning in TX100-DRM as a
function of time after cholesterol depletion. MRP2 was de-
tected in both low-buoyant density fractions (fr. 4 and 5)
and high density fractions (fr. 7–10) before MbCD treatment
(Fig. 1B). According to the classical deﬁnition, and according
to our previous data with typical raft markers (e.g. caveolin
and src; c.f. [9]), the low-buoyant density fractions correspond
to TX100-insoluble raft membranes (TX100-DRM) and the
high density fractions correspond to TX100-soluble non-raft
membranes. Hinrichs and colleagues [11] showed a seemingly
larger pool of MRP2 in the low-buoyant density fractions in
HepG2 cells. This is due to the fact that in their study equal
amounts of protein were loaded whereas in our study equal
volumes were loaded for gel electrophoresis. MRP2 disap-
peared from low-buoyant density DRM fractions after treat-
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terol; no detectable cholesterol in basolateral and canalicular
membranes by ﬁlipin) and 20 min (76% reduction in total cho-
lesterol). MRP2 reappeared in low-buoyant density DRM
fractions to control levels after subsequent cholesterol replen-
ishment to control levels (Fig 1B). A signiﬁcant fraction of
MRP2 thus dynamically distributes in low-buoyant density
DRM in a cholesterol-dependent manner, while association
of MRP2 with low-buoyant density DRM evidently is not re-
quired for its exclusive localization at the BC membrane.
Previous studies have reported bile acid-mediated (re)distri-
bution of MRP2 to and from the bile canalicular membrane in
a signalling-dependent manner [16–18]. Because association of
MRP2 with DRMs does not inﬂuence its polarized distribu-
tion in the BC membrane, our data suggest that bile acid-med-
iated redistribution of MRP2 to and from bile canalicular
membranes is not likely to be regulated by a dynamic entry
and exit of the protein from cholesterol-rich low-buoyant den-
sity DRMs. However, caution should be taken in comparing
and extrapolating results obtained in diﬀerent experimental
settings.
We next examined whether MRP2 function was aﬀected by
cholesterol depletion and if so, whether this is correlated to its
partitioning in DRM. To measure MRP2 function we em-
ployed CMFDA, a non-ﬂuorescent compound that diﬀuses
into cells. Subsequently, its acetate groups are cleaved oﬀ to
produce green ﬂuorescent CMF and its glutathione conjugate
(CMF-SG). CMF and CMF-SG are speciﬁc substrates of
MRP2 [19]. In control cells and cells treated with MbCD for
10 min, ﬂuorescent CMF/CMF-SG accumulated in the BC lu-
men in an undistinguishable manner, reﬂecting active MRP
function (Fig. 2). Note that the excretion of CMF/CMF-SG
into BC lumens was prevented by the MRP2 inhibitor
MK571 (Fig. 2B) or ATP depletion using metabolic inhibitors
(5 mMNaN3 and 50 mM 2-deoxy-O-glucose; data not shown),Fig. 2. Eﬀect of cholesterol depletion on MRP2 transport function.
(A) HepG2 cells were treated with HBSS or 10 mM MbCD for
indicated period (10 min or 20 min). Cells were washed and subse-
quently assayed for CMF transport (HBSS 20 0, CD 100, CD 20 0). In
some case, cells were further incubated with HBSS (CD20 0 ﬁ HBSS)
or MbCD/cholesterol (CD 20 0 ﬁ CD/Chol) for 30 min to replenish
cholesterol then assayed for CMF transport. Living cell ﬂuorescence
(left panels) and phase contrast (right panels). Arrows indicate BC
lumen in between adjacent HepG2 cells. (B) Quantiﬁcation of
excretion into BC lumens (see Section 2).underscoring that CMF/CMF-SG excretion requires ATP-
dependent MRP activity. In contrast to a 10 min treatment,
cells treated with MbCD for 20 min failed to accumulate ﬂuo-
rescent CMF/CMF-SG in BC lumens (>95% inhibition, Fig
2B) and, instead, accumulated CMF/CMF-SG intracellularly
(Fig. 2A). CMF/CMF-SG excretion into BC lumens was
recovered after cholesterol replenishment, suggesting that the
eﬀect of MbCD on MRP2 function is mediated by cholesterol
(Fig 2).
Yunomae and colleagues demonstrated that treatment of
polarized human colon carcinoma Caco-2 cells with 2,6-di-
O-methyl-b-cyclodextrin (DM-b-CD; 10 mM, 30 min), an ana-
logue of MbCD, slightly but signiﬁcantly decreased the trans-
port function of MRP2, possibly by extracting not only
cholesterol but also transporter itself [20]. Thus, following
treatment with DM-b-CD for 30 min, the amount of MRP2
in cells and the amount of MRP2 released in the medium de-
creased and increased, respectively [17]. Importantly, the treat-
ment conditions used in this study did not cause extraction/
shedding of MRP2 because (i) the localization of MRP2 in
the canalicular membrane was not aﬀected by 10 mM MbCD
treatment (Fig 1A), (ii) MRP2 protein amounts in the crude
membrane fraction as well as in total cell lysate were not af-
fected during the time frame of our experiments (data not
shown), and (iii) MRP2 transport function (Fig. 2) as well as
DRM association (Fig. 1B) was completely and rapidly
(<30 min) restored by replenishing cholesterol. In contrast to
our results, Yunomae and colleagues [20] found no eﬀect of
MbCD onMRP2 function in Caco-2 cell monolayers. This dis-
crepancy may reﬂect the eﬃciency by which cholesterol was de-
pleted in the respective studies (76% depletion of total cellular
cholesterol in our study versus 30% depletion of total cellular
cholesterol in Yunomaes study), and/or reﬂect diﬀerences be-
tween the cell types (hepatic versus intestinal) studied.
We performed multiple control experiments to rule out pos-
sible cytotoxic side eﬀects of MbCD treatment that may have
resulted in the inhibition of MRP2 activity and consequent loss
of ﬂuorescence accumulation in the BC lumens. We ﬁnd no in-
crease in overall cytotoxicity of MbCD treatment as monitored
in a lactate dehydrogenase (LDH) and cellular ATP leakage
assay (Fig. 3A and B). ATP release into the medium was also
negligible after 20 min incubation with MbCD (Fig. 3B). Since
the molecular weights of CMF (MW = 465) and CMF-SG
(MW = 736) are comparable to or bigger than that of ATP
(MW = 309), it is unlikely that CMF/CMF-SG leaked out ofFig. 3. Eﬀect of MbCD treatment on plasma membrane integrity and
cell viability. Cells were treated with HBSS (Cont) or 10 mM MbCD
(CD) for 20 min at 37 C. (A) LDH released into the medium was
measured and shown as % of cells treated with 1% TX100 (1% TX). (B)
ATP contents inside cells and released into the medium were separately
measured. Cells treated with 1% TX100 (1% TX) and cells treated with
metabolic inhibitors (ATP dep) were shown aside. Data are
means ± S.D. of triplicate determinations. ND: not detected.
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BC lumens. We also examined tight junction function in
MbCD-treated cells to rule out that tight junctions may have
been leaky. The intactness of tight junctions was determined
using C6-NBD-sphingomyelin (C6-NBD-SM), which readily
partitions into the basolateral plasma membrane outer leaﬂet.
The rationale of this experiment is that if the tight junction
barrier function is intact, C6-NBD-SM should not be accessi-
ble to the apical BC membrane during a short term incubation
on ice, which prevents intracellular traﬃcking of the lipid
species [15]. HepG2 cells treated with MbCD for 20 min did
not show any C6-NBD-SM ﬂuorescence in BC membranes,
suggesting intact tight junction integrity (Fig. 4A). As a posi-
tive control, C6-NBD-SM ﬂuorescence was readily observed
in the BC membranes of cells treated with EGTA, a Ca2+
chelator known to open tight junction (Fig. 4A). In addition,
indistinguishable ZO-1 staining was observed in control and
MbCD-treated cells (Fig 4B). In conclusion, our results
indicate that in HepG2 cells cholesterol is necessary for the
association of MRP2 with DRM and MRP2 transport func-
tion, but the association of MRP2 with DRM is not necessary
for its transport function.
The precise molecular mechanism by which cholesterol
regulates MRP2 transport function is not known at present.
MDR1 function can be stimulated in the presence of choles-
terol. Recently, Kimura and colleagues proposed that choles-
terol may support the recognition of smaller compounds by
adjusting the substrate-binding site of MDR1. They demon-
strated that cholesterol directly binds to puriﬁed MDR1 in a
detergent-soluble form and the eﬀects of cholesterol on the
Km values of drug-stimulated ATPase activity were inversely
correlated with the molecular mass of the compound drugs
tested [21,22]. As most MDR1 substrates are highly hydropho-
bic [23] and MDR1 may present a substrate recognition pocket
within the lipid bilayer [24], cholesterol would easily interact
with the site where drugs are recognized. Because MRP2 sub-Fig. 4. Eﬀect of MbCD treatment on tight junction functionality. Cells
were treated with HBSS (HBSS 20 0) or 10 mM MbCD (CD 20 0) for
20 min at 37 C and then immediately observed for live C6-NBD-SM
ﬂuorescence or ﬁxed and processed for indirect immunostaining of ZO-
1. (A) Cells were incubated with 4 lM C6-NBD-SM for 5 min on ice,
then observed under inverted ﬂuorescence microscopy. Living cell
ﬂuorescence (left panels) and phase contrast (right panels) images are
shown. As a positive control, cells were pretreated with 2 mM EGTA
to open tight junction (EGTA). Arrows indicate BC regions. (B) Tight
junction component ZO-1 and BC marker protein Rdx were visualized
by indirect immunoﬂuorescence staining. Images are the representa-
tives of typical data.strates are of hydrophobic nature to some extent [25] and be-
cause the transmembrane domains of MRP2 are also
involved in substrate recognition/transport [26–28], it is possi-
ble that cholesterol similarly aﬀects the transport function of
MRP2 by interacting with its putative substrate-binding site
and transport substrates.
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